Codix Pharma Limited is a fast growing pharmaceutical company with offices in Lagos (Nigeria) and London (UK). Our vision is to become the market leader in cardio-metabolic care (diabetes, hypertension and CHD) in Nigeria. We intend to do this through patients’ education, introduction of innovative, quality but affordable products (medicines and monitoring devices) and development of 21st century sales team.
The Directors of Codix have over 25 years combined experience in the Pharmaceutical Industry, particularly in the sales & marketing of cardio-metabolic therapy area (diabetes, hypertension and cardiovascular) both locally and in the United Kingdom. With our immense pharmaceutical experience in the United Kingdom, obtained from working in various roles with multi-national pharmaceutical companies, we feel very obliged to contribute into the shaping and improving the health of our nation, particularly in the areas of diabetes, hypertension & heart diseases.
As part of the company’s commitment to diabetes treatment and control in Nigeria, and in line with its vision towards improving the health of the nation, it is keen to enter into Public Private Partnership with every willing arm of the government to bring about an effective management & control of diabetes. Diabetes is a growing concern world-wide. There is probably an un-diagnosed diabetic patient for every known diagnosed diabetic patient. For developing countries, there is a projected increase of 170% cases.
Since the inception of Codix in 2004, we have been developing our diabetes portfolio including Glucodix (metformin HCL), FineTest Meter (Blood Glucose Meter), FineTest Strips, Lancet Needles and Clover A1c (HbA1c machine). Hypertension is a common finding in the diabetic patient. The combination of diabetes and hypertension is lethal to the cardiovascular system. The risk of the occurrence of strokes, myocardial infarctions, heart failure, and renal failure is increased in the diabetic patient with hypertension. Going by the current definition of hypertension by the 7th Joint National Committee on Prevention, Detection, Evaluation & Treatment of High Blood Pressure (JNC 7) guidelines, 20%-25% Nigerians would be classified as hypertensive.